Based on the findings reported here, the safety and immunogenicity of CVGBM are evaluated in a first-in-human Phase I trial (NCT05938387) in HLA-A*02:01-positive patients with newly diagnosed MGMT-unmethylated GBM (CNS WHO Grade 4) who had surgical resection and completed radiotherapy with or without concomitant temozolomide. Here, MGMT is linked to glioblastoma.